Amgen's olpasiran may fill critical treatment gap in lowering Lp(a)

US biotech major Amgen’s (Nasdaq: AMGN) olpasiran, a small interfering RNA (siRNA), is making strides in reducing lipoprotein [Lp(a)] levels significantly in patients with cardiovascular disease. This is noteworthy as elevated Lp(a) is considered a potent risk factor for heart disease and stroke.

It also underscores olpasiran's potential to address a vital treatment gap, representing a pivotal advancement in the realm of dyslipidemia, according to industry analyst GlobalData.

The latest data from the final analysis of the Phase II OCEAN(a)-DOSE study showed that olpasiran reduced Lp(a) levels in patients by 95%. This study, which resulted from the off-treatment extension period, showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a) for nearly a year after their last dose.